PL3575293T3 - Sól etanosulfonianowa n-{5-[(6,7-dimetoksy-4-chinolinyl)oksy]- 2-pirydy-nylo}-2,5-diokso-1-fenylo-1,2,5,6,7,8-heksahydro-3-chinolinokarboksamidu - Google Patents

Sól etanosulfonianowa n-{5-[(6,7-dimetoksy-4-chinolinyl)oksy]- 2-pirydy-nylo}-2,5-diokso-1-fenylo-1,2,5,6,7,8-heksahydro-3-chinolinokarboksamidu

Info

Publication number: PL3575293T3
Authority: PL; Poland
Prior art keywords: quinolinecarboxamide; hexahydro; dioxo; quinolinyl; pyridinyl
Prior art date: 2017-01-26

Application number

PL18744970T

Other languages

English (en)

Inventor

Takahiro Nekado

Hideomi KIJIMA

Shizuka Ono

Toshihiko Nishiyama

Original Assignee

Ono Pharmaceutical Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-01-26

Filing date

2018-01-25

Publication date

2021-09-06

2018-01-25 Application filed by Ono Pharmaceutical Co., Ltd. filed Critical Ono Pharmaceutical Co., Ltd.

2021-09-06 Publication of PL3575293T3 publication Critical patent/PL3575293T3/pl

Links

-1 6,7-dimethoxy-4-quinolinyl Chemical group 0.000 title 1
CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Hematology (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

PL18744970T 2017-01-26 2018-01-25 Sól etanosulfonianowa n-{5-[(6,7-dimetoksy-4-chinolinyl)oksy]- 2-pirydy-nylo}-2,5-diokso-1-fenylo-1,2,5,6,7,8-heksahydro-3-chinolinokarboksamidu PL3575293T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2017011835		2017-01-26
EP18744970.7A EP3575293B1 (en)	2017-01-26	2018-01-25	Ethanesulfonate salt of n-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide
PCT/JP2018/002250 WO2018139527A1 (ja)	2017-01-26	2018-01-25	キノリン誘導体のエタンスルホン酸塩

Publications (1)

Publication Number	Publication Date
PL3575293T3 true PL3575293T3 (pl)	2021-09-06

Family

ID=62979439

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL18744970T PL3575293T3 (pl)	2017-01-26	2018-01-25	Sól etanosulfonianowa n-{5-[(6,7-dimetoksy-4-chinolinyl)oksy]- 2-pirydy-nylo}-2,5-diokso-1-fenylo-1,2,5,6,7,8-heksahydro-3-chinolinokarboksamidu

Country Status (21)

Country	Link
US (1)	US10836747B2 (pl)
EP (1)	EP3575293B1 (pl)
JP (1)	JP6605763B2 (pl)
KR (1)	KR102571911B1 (pl)
CN (2)	CN110225908A (pl)
AU (1)	AU2018211801B2 (pl)
CA (1)	CA3051605C (pl)
DK (1)	DK3575293T3 (pl)
ES (1)	ES2872923T3 (pl)
HU (1)	HUE054883T2 (pl)
IL (1)	IL268221B (pl)
MX (1)	MX379140B (pl)
MY (1)	MY196680A (pl)
PH (1)	PH12019501693A1 (pl)
PL (1)	PL3575293T3 (pl)
PT (1)	PT3575293T (pl)
RU (1)	RU2019123279A (pl)
SG (1)	SG11201906819VA (pl)
TW (1)	TWI779007B (pl)
WO (1)	WO2018139527A1 (pl)
ZA (1)	ZA201904895B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20200197385A1 (en) *	2017-08-23	2020-06-25	Ono Pharmaceutical Co., Ltd.	Therapeutic agent for cancer containing axl inhibitor as active ingredient
US11826363B2 (en)	2017-10-13	2023-11-28	Ono Pharmaceutical Co., Ltd.	Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
WO2024046292A1 (zh) *	2022-08-30	2024-03-07	药捷安康(南京)科技股份有限公司	喹啉衍生物抑制剂的晶型及其制备方法及用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6428234B1 (en) *	2000-01-07	2002-08-06	Closure Medical Corporation	Adhesive applicator tips with improved flow properties
EP1248869A2 (en) *	2000-01-07	2002-10-16	Transform Pharmaceuticals, Inc.	High-throughput formation, identification, and analysis of diverse solid-forms
JO2787B1 (en)	2005-04-27	2014-03-15	امجين إنك,	Alternative amide derivatives and methods of use
WO2007033196A1 (en)	2005-09-14	2007-03-22	Bristol-Myers Squibb Company	Met kinase inhibitors
JP2009537632A (ja)	2006-05-19	2009-10-29	バイエル・ヘルスケア・アクチェンゲゼルシャフト	過剰増殖性障害および血管新生障害の処置に有用なピリドンカルボキサミド誘導体
JP2009539878A (ja)	2006-06-08	2009-11-19	アレイバイオファーマ、インコーポレイテッド	キノリン化合物および使用方法
RU2010146474A (ru)	2008-04-16	2012-05-27	Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. (De)	Производные хинолина в качестве ингибиторов axl киназ
UY31800A (es)	2008-05-05	2009-11-10	Smithkline Beckman Corp	Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AU2009246263B2 (en)	2008-05-14	2014-08-21	Amgen Inc.	Combinations VEGF(R) inhibitors and hepatocyte growth factor (c-Met) inhibitors for the treatment of cancer
JP2012504606A (ja)	2008-10-01	2012-02-23	ラディックインスティテュートフォーキャンサーリサーチ	癌の治療方法
JP2010178651A (ja)	2009-02-04	2010-08-19	Eisai R & D Management Co Ltd	Ｈｇｆｒ阻害物質の作用検定方法
JP5525612B2 (ja)	2010-07-23	2014-06-18	国立大学法人東京大学	含窒素複素環誘導体
JP5791412B2 (ja)	2010-07-26	2015-10-07	日本碍子株式会社	セラミックヒーター
EP2423208A1 (en)	2010-08-28	2012-02-29	Lead Discovery Center GmbH	Pharmaceutically active compounds as Axl inhibitors
WO2012080729A2 (en)	2010-12-14	2012-06-21	Electrophoretics Limited	CASEIN KINASE 1δ (CK1δ) INHIBITORS
CN102816175B (zh)	2011-06-09	2015-12-16	上海汇伦生命科技有限公司	一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
JP2013074633A (ja)	2011-09-26	2013-04-22	Oki Electric Ind Co Ltd	スイッチング電源装置及び現金自動預け払い装置
SG11201402004YA (en)	2011-11-14	2014-05-29	Cephalon Inc	Uracil derivatives as axl and c-met kinase inhibitors
TWI649308B (zh)	2013-07-24	2019-02-01	小野藥品工業股份有限公司	喹啉衍生物

2018
- 2018-01-25 TW TW107102692A patent/TWI779007B/zh active
- 2018-01-25 CN CN201880008442.7A patent/CN110225908A/zh active Pending
- 2018-01-25 CA CA3051605A patent/CA3051605C/en active Active
- 2018-01-25 MX MX2019008787A patent/MX379140B/es unknown
- 2018-01-25 KR KR1020197021641A patent/KR102571911B1/ko active Active
- 2018-01-25 JP JP2018564622A patent/JP6605763B2/ja active Active
- 2018-01-25 SG SG11201906819VA patent/SG11201906819VA/en unknown
- 2018-01-25 DK DK18744970.7T patent/DK3575293T3/da active
- 2018-01-25 AU AU2018211801A patent/AU2018211801B2/en active Active
- 2018-01-25 CN CN202411731946.5A patent/CN119707932A/zh active Pending
- 2018-01-25 WO PCT/JP2018/002250 patent/WO2018139527A1/ja not_active Ceased
- 2018-01-25 ES ES18744970T patent/ES2872923T3/es active Active
- 2018-01-25 PL PL18744970T patent/PL3575293T3/pl unknown
- 2018-01-25 PT PT187449707T patent/PT3575293T/pt unknown
- 2018-01-25 MY MYPI2019004265A patent/MY196680A/en unknown
- 2018-01-25 US US16/480,514 patent/US10836747B2/en active Active
- 2018-01-25 HU HUE18744970A patent/HUE054883T2/hu unknown
- 2018-01-25 RU RU2019123279A patent/RU2019123279A/ru unknown
- 2018-01-25 EP EP18744970.7A patent/EP3575293B1/en active Active
2019
- 2019-07-22 IL IL268221A patent/IL268221B/en unknown
- 2019-07-23 PH PH12019501693A patent/PH12019501693A1/en unknown
- 2019-07-25 ZA ZA2019/04895A patent/ZA201904895B/en unknown

Also Published As

Publication number	Publication date
MX2019008787A (es)	2019-09-11
IL268221A (en)	2019-09-26
NZ755665A (en)	2024-07-26
ZA201904895B (en)	2025-10-29
CN119707932A (zh)	2025-03-28
CN110225908A (zh)	2019-09-10
JPWO2018139527A1 (ja)	2019-06-27
ES2872923T3 (es)	2021-11-03
WO2018139527A9 (ja)	2018-09-20
MX379140B (es)	2025-03-10
PH12019501693A1 (en)	2020-06-15
EP3575293B1 (en)	2021-03-10
CA3051605A1 (en)	2018-08-02
PT3575293T (pt)	2021-05-25
IL268221B (en)	2022-03-01
AU2018211801A1 (en)	2019-08-15
RU2019123279A3 (pl)	2021-03-31
TW201833099A (zh)	2018-09-16
KR102571911B1 (ko)	2023-08-28
RU2019123279A (ru)	2021-02-26
SG11201906819VA (en)	2019-08-27
MY196680A (en)	2023-04-29
AU2018211801B2 (en)	2021-07-08
EP3575293A1 (en)	2019-12-04
JP6605763B2 (ja)	2019-11-13
TWI779007B (zh)	2022-10-01
EP3575293A4 (en)	2019-12-04
HUE054883T2 (hu)	2021-10-28
US20190389837A1 (en)	2019-12-26
DK3575293T3 (da)	2021-04-26
US10836747B2 (en)	2020-11-17
CA3051605C (en)	2024-06-25
WO2018139527A1 (ja)	2018-08-02
KR20190111035A (ko)	2019-10-01
BR112019015352A2 (pt)	2020-03-10

Publication	Publication Date	Title
ZA202102356B (en)	2022-07-27	Sting agonistic compound
ZA201908367B (en)	2021-07-28	Molten salt reactor
ZA202003717B (en)	2022-01-26	Sulfone pyridine alkyl amide-substituted heteroaryl compounds
EP3488490A4 (en)	2020-04-08	ANTENNA COMBINER
PT3466934T (pt)	2024-04-30	Compostos de sulfonamida ou seus sais como inibidores da ribonucleótido-redutase para o tratamento de cancro
IL271399A (en)	2020-01-30	Methods for the preparation of heterocyclic 3,1-benzodioxole compounds
IL275415A (en)	2020-07-30	sGC fans
IL268863A (en)	2019-10-31	Pesticide compounds
GB2552553B (en)	2022-03-16	Motion feedthrough
NO20161285A1 (en)	2017-08-14	Motion compensating crane system
HUE054883T2 (hu)	2021-10-28	N-{5-[(6,7-dimetoxi-4-kinolinil)oxi]-2-piridinil}-2,5-dioxo-1-fenil-1,2,5,6,7,8-hexahidro-3-kinolinkarboxamid etánszulfonát sója
IL270148B (en)	2022-02-01	n-(4-pyridyl)nicotinamide compound or a salt thereof
IL282731A (en)	2021-06-30	Organogulfonic compounds
GB201705177D0 (en)	2017-05-17	Device to aid movement of substance from the eye
ITUB20153493A1 (it)	2017-03-09	Attrezzatura per l'applicazione di borchie.
IL274084A (en)	2020-06-30	Comb for the treatment of dandruff
GB201809460D0 (en)	2018-07-25	Salt form
IL253717A0 (en)	2017-09-28	Crystalline form of s-(4-(3-fluoro-3-methylbutyryloxy)but-2-ynyl)6a,9a-difluoro-17a,-(furan-2-yl)carbonyloxy-11b-hydroxy-16a-methy1-3 -oxoandrosta-1,4-diene-17b-carbothioate
HUP1700542A2 (en)	2019-02-28	Nucleosides modified by 5'-linker
GB201717983D0 (en)	2017-12-13	Improvements to the operation of electromagnetic actuators
GB201704645D0 (en)	2017-05-10	Mammalian Trade-off-Weight"(mTOW)
GB201711900D0 (en)	2017-09-06	Salt
GB201711901D0 (en)	2017-09-06	Salt
GB201711899D0 (en)	2017-09-06	Salt
AP01024S1 (en)	2019-02-14	Heart for 2 fetoscope